BACKGROUND: The overall prognosis of @entity1582 has improved significantly over the last 15 years. We wondered whether the overall improvement would also be seen in unselected @entity1 in an academic center in Northwest Louisiana with a high proportion of minority @entity1 , and if second @entity5 are relevant for our @entity1 . MATERIALS AND METHODS: Between 1998 and 2009, 215 @entity1 were treated for @entity1582 at our center and had complete follow-up until May 2013. RESULTS: The mean survival of @entity1 with @entity1582 increased from 3.25 to 5.34 years, which is comparable to @entity1 treated at larger centers. No prognostic difference was observed in the subgroups of @entity1582 @entity1 . Among 215 @entity1 followed for the development of @entity5 , 16 already had a preexisting or concomitant malignancy (7.4%) and 10 developed @entity5 . Our data indicate a significant background of histologically unrelated @entity5 and a cumulative incidence of new @entity5 of about 20% after 10 years of follow-up. Based on SEER data, preexisting or @entity5 were not statistically increased in our population. CONCLUSIONS: The use of autologous transplantation and the introduction of new agents resulted in a significant improvement in the prognosis of @entity1582 . Other @entity5 are not statistically increased before or after @entity1582 is diagnosed and are not prognostically relevant.

The Shreveport XXXX Experience: Survival, Risk Factors and Other @entity5 in the Age of Stem Cell Transplantation.

@entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['secondary cancers', 'cancers', 'malignant neoplasms']
@entity1582 :: (MESH:D009101,Disease) :: ['Myeloma']
